# UTOLA: UTerin OLAparib

> **NCT03745950** · PHASE2 · COMPLETED · sponsor: **ARCAGY/ GINECO GROUP** · enrollment: 147 (actual)

## Conditions studied

- Endometrial Carcinoma

## Interventions

- **DRUG:** Olaparib Oral Capsule
- **DRUG:** Placebo oral capsule

## Key facts

- **NCT ID:** NCT03745950
- **Lead sponsor:** ARCAGY/ GINECO GROUP
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-01
- **Primary completion:** 2023-05-22
- **Final completion:** 2024-09-24
- **Target enrollment:** 147 (ACTUAL)
- **Last updated:** 2024-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03745950

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03745950, "UTOLA: UTerin OLAparib". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03745950. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*